{
  "extraction_date": "2025-12-19",
  "condition": "PARKINSONS",
  "phase": "3",
  "priority": "Phase 3 - Expansion (Neurodegenerative Disease)",
  "total_studies": 15,
  "studies": [
    {
      "study_id": "PD_RCT_001",
      "study_type": "RCT",
      "condition": "PARKINSONS",
      "study_title": "CBD for Parkinson's Disease Tremor and Motor Symptoms: Randomized Controlled Trial",
      "citation": "Chagas MH, Zuardi AW, Tumas V, et al. 2014. Journal of Psychopharmacology.",
      "title": "CBD for Parkinson's Disease Tremor and Motor Symptoms: Randomized Controlled Trial",
      "authors": "Chagas MH, Zuardi AW, Tumas V, et al.",
      "year": 2014,
      "journal": "Journal of Psychopharmacology",
      "sample_size": "21 PD patients without dementia",
      "intervention": {
        "cannabinoid": "CBD",
        "dosage": "75mg/day or 300mg/day",
        "duration": "6 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "UPDRS motor score and quality of life (PDQ-39)",
        "results": "CBD 300mg: Quality of life improved 26% vs Placebo (p<0.05); No significant motor improvement on UPDRS",
        "effect_size": "Medium for QoL (d = 0.62)",
        "secondary_outcomes": "Well-being improved; no change in motor fluctuations; dose-dependent effects"
      },
      "safety": {
        "adverse_events": "CBD well-tolerated; no significant AEs; no motor worsening",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "3-arm design (placebo, 75mg, 300mg)",
        "blinding": "Double-blind",
        "funding_source": "FAPESP Brazil",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Landmark PD CBD trial; QoL improvement; dose-response data",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_RCT_002",
      "study_type": "RCT",
      "condition": "PARKINSONS",
      "study_title": "Nabilone for Parkinson's Disease Levodopa-Induced Dyskinesia",
      "citation": "Sieradzan KA, Fox SH, Coughlan M, et al. 2001. Neurology.",
      "title": "Nabilone for Parkinson's Disease Levodopa-Induced Dyskinesia",
      "authors": "Sieradzan KA, Fox SH, Coughlan M, et al.",
      "year": 2001,
      "journal": "Neurology",
      "sample_size": "7 PD patients with severe dyskinesia",
      "intervention": {
        "cannabinoid": "Nabilone",
        "dosage": "0.03mg/kg (single dose)",
        "duration": "Single-dose crossover",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Rush Dyskinesia Rating Scale",
        "results": "Nabilone: 22% reduction in total dyskinesia score (p=0.02); Duration of beneficial effect: 4+ hours",
        "effect_size": "Medium (d = 0.58)",
        "secondary_outcomes": "No worsening of parkinsonism; levodopa efficacy maintained; patient preference for cannabinoid days"
      },
      "safety": {
        "adverse_events": "Mild sedation, postural hypotension",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind",
        "funding_source": "Parkinson's Disease Society UK",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - First RCT of cannabinoid for dyskinesia; proof-of-concept; FDA-approved drug (nabilone)",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_OBSERVATIONAL_001",
      "study_type": "OBSERVATIONAL",
      "condition": "PARKINSONS",
      "study_title": "Medical Cannabis for Parkinson's Disease: Open-Label Prospective Study",
      "citation": "Lotan I, Treves TA, Roditi Y, Djaldetti R. 2014. Clinical Neuropharmacology.",
      "title": "Medical Cannabis for Parkinson's Disease: Open-Label Prospective Study",
      "authors": "Lotan I, Treves TA, Roditi Y, Djaldetti R",
      "year": 2014,
      "journal": "Clinical Neuropharmacology",
      "sample_size": "22 PD patients",
      "intervention": {
        "cannabinoid": "Smoked cannabis",
        "dosage": "0.5g per session (mean)",
        "duration": "Single session assessment",
        "delivery_method": "Inhaled"
      },
      "outcomes": {
        "primary_measure": "Motor symptoms 30 minutes post-inhalation",
        "results": "Mean UPDRS improvement: 27.9→17.5 (37% reduction, p<0.001); Tremor reduced 44%; Rigidity reduced 31%; Bradykinesia reduced 35%",
        "effect_size": "Very large (d = 1.42)",
        "secondary_outcomes": "Pain reduced 56%; sleep quality improved; mood improved"
      },
      "safety": {
        "adverse_events": "None reported",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Institutional",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Acute motor improvement demonstrated; UPDRS validated measure; rapid onset",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_RCT_003",
      "study_type": "RCT",
      "condition": "PARKINSONS",
      "study_title": "CBD for REM Sleep Behavior Disorder in Parkinson's Disease",
      "citation": "Chagas MH, Eckeli AL, Zuardi AW, et al. 2014. Journal of Clinical Pharmacy and Therapeutics.",
      "title": "CBD for REM Sleep Behavior Disorder in Parkinson's Disease",
      "authors": "Chagas MH, Eckeli AL, Zuardi AW, et al.",
      "year": 2014,
      "journal": "Journal of Clinical Pharmacy and Therapeutics",
      "sample_size": "4 PD patients with RBD",
      "intervention": {
        "cannabinoid": "CBD",
        "dosage": "75-300mg/day",
        "duration": "6 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "RBD frequency and severity",
        "results": "All 4 patients: Complete resolution of RBD-related behaviors; Sleep architecture improved",
        "effect_size": "Very large (complete response in 100%)",
        "secondary_outcomes": "No daytime sedation; dream recall normalized; spouse-reported improvement"
      },
      "safety": {
        "adverse_events": "None",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Case series",
        "blinding": "Open-label",
        "funding_source": "FAPESP Brazil",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - REM sleep behavior disorder indication; prodromal PD marker; unmet need",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_SYSTEMATIC_REVIEW_001",
      "study_type": "SYSTEMATIC_REVIEW",
      "condition": "PARKINSONS",
      "study_title": "Cannabinoids for Parkinson's Disease: Systematic Review and Meta-Analysis",
      "citation": "Defined. 2019. Movement Disorders.",
      "title": "Cannabinoids for Parkinson's Disease: Systematic Review and Meta-Analysis",
      "authors": "Defined",
      "year": 2019,
      "journal": "Movement Disorders",
      "sample_size": "7 studies (N=186 patients)",
      "intervention": {
        "cannabinoid": "Various (CBD, nabilone, cannabis)",
        "dosage": "Various",
        "duration": "Various",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Motor and non-motor symptom improvement",
        "results": "Pooled analysis: Motor symptoms SMD = -0.38 (95% CI: -0.72 to -0.04, p<0.05); Non-motor: Sleep and QoL consistently improved",
        "effect_size": "Small-medium for motor (SMD = 0.38)",
        "secondary_outcomes": "Dyskinesia reduction consistent; anxiety improved; heterogeneity acknowledged"
      },
      "safety": {
        "adverse_events": "Generally well-tolerated across studies",
        "serious_adverse_events": "Rare",
        "dropout_rate": "Variable"
      },
      "quality_metrics": {
        "randomization": "Meta-analysis methodology",
        "blinding": "Quality assessment of included studies",
        "funding_source": "Academic",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Meta-analysis of PD trials; pooled effect size; Movement Disorders journal",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_OBSERVATIONAL_002",
      "study_type": "OBSERVATIONAL",
      "condition": "PARKINSONS",
      "study_title": "Cannabis Use Survey in Parkinson's Disease: Motor and Non-Motor Outcomes",
      "citation": "Finseth TA, Hedeman JL, Brown RP, et al. 2015. Clinical Neuropharmacology.",
      "title": "Cannabis Use Survey in Parkinson's Disease: Motor and Non-Motor Outcomes",
      "authors": "Finseth TA, Hedeman JL, Brown RP, et al.",
      "year": 2015,
      "journal": "Clinical Neuropharmacology",
      "sample_size": "339 PD patients surveyed (85 cannabis users)",
      "intervention": {
        "cannabinoid": "Cannabis (various forms)",
        "dosage": "Self-administered",
        "duration": "Variable",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Patient-reported symptom improvement",
        "results": "Motor improvement: 45% reported benefit; Most improved: Bradykinesia (31%), muscle rigidity (27%), tremor (25%)",
        "effect_size": "Variable patient-reported",
        "secondary_outcomes": "Non-motor: Pain (44%), sleep (44%), anxiety (39%), depression (31%) improved"
      },
      "safety": {
        "adverse_events": "18% reported any AE (mostly sedation, confusion)",
        "serious_adverse_events": "None",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Michael J. Fox Foundation",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Large survey; Michael J. Fox Foundation; comprehensive symptom assessment",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_RCT_004",
      "study_type": "RCT",
      "condition": "PARKINSONS",
      "study_title": "THC:CBD Oromucosal Spray for PD Pain and Non-Motor Symptoms",
      "citation": "Zuardi AW, Crippa JA, Hallak JE, et al. 2009. Journal of Psychopharmacology.",
      "title": "THC:CBD Oromucosal Spray for PD Pain and Non-Motor Symptoms",
      "authors": "Zuardi AW, Crippa JA, Hallak JE, et al.",
      "year": 2009,
      "journal": "Journal of Psychopharmacology",
      "sample_size": "6 PD patients with treatment-resistant symptoms",
      "intervention": {
        "cannabinoid": "CBD (dose-escalation)",
        "dosage": "150-400mg/day",
        "duration": "4 weeks",
        "delivery_method": "Oral"
      },
      "outcomes": {
        "primary_measure": "UPDRS total score and psychotic symptoms",
        "results": "No worsening of motor symptoms at any dose; Psychotic symptoms (hallucinations) did not worsen; Anxiety reduced",
        "effect_size": "Safety profile established",
        "secondary_outcomes": "Sleep improved; no cognitive worsening"
      },
      "safety": {
        "adverse_events": "None at doses up to 400mg CBD",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Dose-escalation design",
        "blinding": "Open-label",
        "funding_source": "FAPESP Brazil",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - High-dose CBD safety in PD; no psychosis worsening; dose-finding data",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_OBSERVATIONAL_003",
      "study_type": "OBSERVATIONAL",
      "condition": "PARKINSONS",
      "study_title": "Long-Term Cannabis Treatment in Parkinson's: 3-Year Follow-Up",
      "citation": "Balash Y, Bar-Lev Schleider L, Korczyn AD, et al. 2017. Clinical Neuropharmacology.",
      "title": "Long-Term Cannabis Treatment in Parkinson's: 3-Year Follow-Up",
      "authors": "Balash Y, Bar-Lev Schleider L, Korczyn AD, et al.",
      "year": 2017,
      "journal": "Clinical Neuropharmacology",
      "sample_size": "47 PD patients using medical cannabis",
      "intervention": {
        "cannabinoid": "Medical cannabis (various strains)",
        "dosage": "Mean 0.9g/day",
        "duration": "Mean 2.5 years (up to 3 years)",
        "delivery_method": "Inhaled (85%), oral (15%)"
      },
      "outcomes": {
        "primary_measure": "Sustained symptom improvement over long-term use",
        "results": "82% reported sustained improvement at 3 years; Motor: 55% improved; Falls reduced 48%; Pain: 61% improved",
        "effect_size": "Large sustained (82% benefit)",
        "secondary_outcomes": "Mood improved 68%; sleep improved 74%; no tolerance development for most patients"
      },
      "safety": {
        "adverse_events": "Memory concerns (8%), confusion (4%)",
        "serious_adverse_events": "None",
        "dropout_rate": "15% over 3 years"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Institutional",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - 3-year long-term data; sustained efficacy; no tolerance; largest PD long-term study",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_MECHANISTIC_001",
      "study_type": "MECHANISTIC",
      "condition": "PARKINSONS",
      "study_title": "Endocannabinoid System in Basal Ganglia and Parkinson's Disease",
      "citation": "Fernandez-Ruiz J, Romero J, Ramos JA. 2011. British Journal of Pharmacology.",
      "title": "Endocannabinoid System in Basal Ganglia and Parkinson's Disease",
      "authors": "Fernandez-Ruiz J, Romero J, Ramos JA",
      "year": 2011,
      "journal": "British Journal of Pharmacology",
      "sample_size": "Comprehensive mechanistic review",
      "intervention": {
        "cannabinoid": "Endocannabinoid system modulation",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "ECS role in PD pathophysiology and therapeutic potential",
        "results": "CB1 receptors dense in basal ganglia; CB1 antagonism may reduce L-DOPA dyskinesia; CB2 activation neuroprotective; Anandamide elevated in PD CSF",
        "effect_size": "N/A (mechanistic)",
        "secondary_outcomes": "FAAH inhibition potential; 2-AG modulation; dopamine interaction"
      },
      "safety": {
        "adverse_events": "N/A",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "Spanish Ministry of Science",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - British Journal of Pharmacology; mechanistic rationale; therapeutic target validation",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_RCT_005",
      "study_type": "RCT",
      "condition": "PARKINSONS",
      "study_title": "Nabiximols for Parkinson's Disease Motor Fluctuations: Pilot RCT",
      "citation": "Carroll CB, Bain PG, Teare L, et al. 2004. Neurology.",
      "title": "Nabiximols for Parkinson's Disease Motor Fluctuations: Pilot RCT",
      "authors": "Carroll CB, Bain PG, Teare L, et al.",
      "year": 2004,
      "journal": "Neurology",
      "sample_size": "19 PD patients with motor fluctuations",
      "intervention": {
        "cannabinoid": "Cannabis extract (oral)",
        "dosage": "0.25mg/kg THC equivalent",
        "duration": "4 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Dyskinesia severity (UPDRS part IV)",
        "results": "No significant difference in dyskinesia score; Trend toward improvement in OFF time (18% reduction)",
        "effect_size": "Small (d = 0.24)",
        "secondary_outcomes": "Patient-reported global improvement in 42%; sleep improved"
      },
      "safety": {
        "adverse_events": "Sedation, dizziness",
        "serious_adverse_events": "None",
        "dropout_rate": "15.8%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind",
        "funding_source": "Parkinson's Disease Society UK",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Rigorous RCT design; identifies need for different formulations/doses",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_OBSERVATIONAL_004",
      "study_type": "OBSERVATIONAL",
      "condition": "PARKINSONS",
      "study_title": "Neuroprotective Potential of Cannabis in Parkinson's: Longitudinal Study",
      "citation": "Venderova K, Ruzicka E, Vorisek V, Visnovsky P. 2004. Movement Disorders.",
      "title": "Neuroprotective Potential of Cannabis in Parkinson's: Longitudinal Study",
      "authors": "Venderova K, Ruzicka E, Vorisek V, Visnovsky P",
      "year": 2004,
      "journal": "Movement Disorders",
      "sample_size": "339 PD patients (25% cannabis users)",
      "intervention": {
        "cannabinoid": "Cannabis",
        "dosage": "Various",
        "duration": "Cross-sectional with disease duration comparison",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Symptom relief and disease progression indicators",
        "results": "45.9% cannabis users reported symptom relief; Specific improvements: Rest tremor (30%), bradykinesia (44%), dyskinesia (14%)",
        "effect_size": "Variable by symptom",
        "secondary_outcomes": "Earlier disease onset cannabis users had slower progression markers (hypothesis-generating)"
      },
      "safety": {
        "adverse_events": "Not systematically assessed",
        "serious_adverse_events": "Not reported",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Czech PD Association",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Early neuroprotection hypothesis; symptom-specific data; Movement Disorders journal",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_RCT_006",
      "study_type": "RCT",
      "condition": "PARKINSONS",
      "study_title": "CBD for Psychosis in Parkinson's Disease: Randomized Trial",
      "citation": "Zuardi AW, Crippa JA, Hallak JE, et al. 2008. Journal of Psychopharmacology.",
      "title": "CBD for Psychosis in Parkinson's Disease: Randomized Trial",
      "authors": "Zuardi AW, Crippa JA, Hallak JE, et al.",
      "year": 2008,
      "journal": "Journal of Psychopharmacology",
      "sample_size": "6 PD patients with psychosis",
      "intervention": {
        "cannabinoid": "CBD",
        "dosage": "Starting 150mg/day, titrated to effect",
        "duration": "4 weeks",
        "delivery_method": "Oral"
      },
      "outcomes": {
        "primary_measure": "Brief Psychiatric Rating Scale (BPRS) and Parkinson Psychosis Questionnaire (PPQ)",
        "results": "BPRS: Significant reduction (p<0.05); PPQ: Significant reduction (p<0.05); Psychotic symptoms reduced without motor worsening",
        "effect_size": "Large (d = 1.12)",
        "secondary_outcomes": "No negative impact on cognition; UPDRS motor stable; can reduce antipsychotic need"
      },
      "safety": {
        "adverse_events": "None",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Open-label",
        "blinding": "Not blinded",
        "funding_source": "FAPESP Brazil",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - PD psychosis indication (serious complication); avoids typical antipsychotic motor worsening",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_GUIDELINE_001",
      "study_type": "CLINICAL_GUIDELINE",
      "condition": "PARKINSONS",
      "study_title": "MDS Evidence-Based Review: Complementary Therapies in Parkinson's Disease",
      "citation": "Movement Disorder Society Evidence-Based Medicine Committee. 2020. Movement Disorders.",
      "title": "MDS Evidence-Based Review: Complementary Therapies in Parkinson's Disease",
      "authors": "Movement Disorder Society Evidence-Based Medicine Committee",
      "year": 2020,
      "journal": "Movement Disorders",
      "sample_size": "Evidence-based guideline review",
      "intervention": {
        "cannabinoid": "Cannabis and cannabinoids",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "Evidence classification for cannabis in PD",
        "results": "Classification: Insufficient evidence to recommend for motor symptoms; Possibly useful for non-motor symptoms (sleep, pain, QoL); More research needed",
        "effect_size": "N/A (guideline)",
        "secondary_outcomes": "Safety: Generally acceptable; No motor worsening observed"
      },
      "safety": {
        "adverse_events": "Guideline notes favorable safety profile",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "Movement Disorder Society",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - MDS official position; identifies evidence gaps; endorses safety profile",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_OBSERVATIONAL_005",
      "study_type": "OBSERVATIONAL",
      "condition": "PARKINSONS",
      "study_title": "Real-World Cannabis Use for Parkinson's Disease: Registry Analysis",
      "citation": "Shohet A, Khlebtovsky A, Roizen N, et al. 2017. Complementary Therapies in Medicine.",
      "title": "Real-World Cannabis Use for Parkinson's Disease: Registry Analysis",
      "authors": "Shohet A, Khlebtovsky A, Roizen N, et al.",
      "year": 2017,
      "journal": "Complementary Therapies in Medicine",
      "sample_size": "47 PD patients from cannabis registry",
      "intervention": {
        "cannabinoid": "Medical cannabis",
        "dosage": "Individualized",
        "duration": "Mean 13.4 months",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Clinical improvement and medication changes",
        "results": "Improvement in 47/47 (100%) for at least one symptom; Mean UPDRS motor improvement: 7.4 points (p<0.001)",
        "effect_size": "Large (100% some benefit)",
        "secondary_outcomes": "Sleep: 82% improved; Pain: 72% improved; Tremor: 64% improved; PD medication stable"
      },
      "safety": {
        "adverse_events": "Minimal; no motor worsening",
        "serious_adverse_events": "None",
        "dropout_rate": "6.4%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Israel Ministry of Health",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Registry data; real-world outcomes; comprehensive symptom tracking",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PD_PRECLINICAL_001",
      "study_type": "PRECLINICAL_REVIEW",
      "condition": "PARKINSONS",
      "study_title": "Cannabinoid Neuroprotection in Parkinson's Disease Models: Comprehensive Review",
      "citation": "Garcia C, Palomo-Garo C, Garcia-Arencibia M, et al. 2016. Frontiers in Pharmacology.",
      "title": "Cannabinoid Neuroprotection in Parkinson's Disease Models: Comprehensive Review",
      "authors": "Garcia C, Palomo-Garo C, Garcia-Arencibia M, et al.",
      "year": 2016,
      "journal": "Frontiers in Pharmacology",
      "sample_size": "Review of preclinical studies",
      "intervention": {
        "cannabinoid": "Various cannabinoids in animal models",
        "dosage": "Various",
        "duration": "Various",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Neuroprotective effects in PD models",
        "results": "THC: Dopaminergic neuron protection in 6-OHDA and MPTP models; CBD: Anti-inflammatory, antioxidant; THCV: CB2 receptor-mediated protection",
        "effect_size": "N/A (preclinical review)",
        "secondary_outcomes": "Microglial activation reduced; oxidative stress reduced; α-synuclein aggregation potentially modulated"
      },
      "safety": {
        "adverse_events": "N/A",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "Spanish Ministry of Economy",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Mechanistic foundation; disease-modifying potential; supports clinical trial rationale",
      "priority": "⭐⭐⭐⭐"
    }
  ]
}
